Paul A Friedman sold $17M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 46,808 shares at an average of $355.31, traded Aug 11, 2025, filed Aug 13, 2025.
Score components
- +15RoleDirector
- +25Trade size$16.6M at market
- +5Share of holdings soldSold 25% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001236927-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | MOption exercise Common Stock10b5-1 | +3,203 | $9.45 | $30k | 190,367 | Aug 13, 2025 |
| Aug 11, 2025 | SOpen-market sale Common Stock10b5-1 | -2,903 | $350.19 | $1.0M | 187,464 | Aug 13, 2025 |
| Aug 11, 2025 | SOpen-market sale Common Stock10b5-1 | -300 | $351.04 | $105k | 187,164 | Aug 13, 2025 |
| Aug 12, 2025 | MOption exercise Common Stock10b5-1 | +43,605 | $9.45 | $412k | 230,769 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -3,303 | $350.93 | $1.2M | 227,466 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -3,202 | $351.59 | $1.1M | 224,264 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -1,382 | $352.61 | $487k | 222,882 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -4,768 | $354.06 | $1.7M | 218,114 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -6,546 | $355.00 | $2.3M | 211,568 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -5,244 | $355.97 | $1.9M | 206,324 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -5,094 | $356.94 | $1.8M | 201,230 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -8,434 | $357.93 | $3.0M | 192,796 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -5,032 | $358.83 | $1.8M | 187,764 | Aug 13, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -600 | $359.81 | $216k | 187,164 | Aug 13, 2025 |
| Aug 11, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,203 | $0.00 | $0 | 172,777 | Aug 13, 2025 |
| Aug 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -43,605 | $0.00 | $0 | 129,172 | Aug 13, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $14M 24,800 shares | -12% | |
| 20Weak | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $10M 18,650 shares | -4% | |
| 50Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,400 shares | -2% | |
| 37Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $2.4M 4,173 shares | -29% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $1.1M 1,958 shares | -16% | |
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $4.4M 8,500 shares | -29% | |
| 53Moderate | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $8.0M 16,575 shares | -86% | |
| 50Moderate | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.2M 7,279 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.0M 7,616 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.